Erica Michelle Stringer-Reasor, MD, University of Alabama at Birmingham, Birmingham, AL, discusses future treatment approaches in breast cancer with brain metastases. In addition to the current treatment regimen of trastuzumab, pertuzumab, and docetaxel for HER2-positive breast cancer, there are treatments that have been recently FDA-approved such as tucatinib. Trials evaluating the aforementioned treatments in an earlier setting, as well as novel therapies effectively targeting brain metastases, are additional research areas of importance. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.